Literature DB >> 25344603

Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).

Kine Marita Knudsen Sand1, Malin Bern1, Jeannette Nilsen2, Bjørn Dalhus3, Kristin Støen Gunnarsen4, Jason Cameron5, Algirdas Grevys1, Karen Bunting6, Inger Sandlie1, Jan Terje Andersen7.   

Abstract

Albumin is an abundant blood protein that acts as a transporter of a plethora of small molecules like fatty acids, hormones, toxins, and drugs. In addition, it has an unusual long serum half-life in humans of nearly 3 weeks, which is attributed to its interaction with the neonatal Fc receptor (FcRn). FcRn protects albumin from intracellular degradation via a pH-dependent cellular recycling mechanism. To understand how FcRn impacts the role of albumin as a distributor, it is of importance to unravel the structural mechanism that determines pH-dependent binding. Here, we show that although the C-terminal domain III (DIII) of human serum albumin (HSA) contains the principal binding site, the N-terminal domain I (DI) is important for optimal FcRn binding. Specifically, structural inspection of human FcRn (hFcRn) in complex with HSA revealed that two exposed loops of DI were in proximity with the receptor. To investigate to what extent these contacts affected hFcRn binding, we targeted selected amino acid residues of the loops by mutagenesis. Screening by in vitro interaction assays revealed that several of the engineered HSA variants showed decreased binding to hFcRn, which was also the case for two missense variants with mutations within these loops. In addition, four of the variants showed improved binding. Our findings demonstrate that both DI and DIII are required for optimal binding to FcRn, which has implications for our understanding of the FcRn-albumin relationship and how albumin acts as a distributor. Such knowledge may inspire development of novel HSA-based diagnostics and therapeutics.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Albumin; Biodegradation; Bioengineering; Fc Receptor; Pharmacokinetics; pH Regulation

Mesh:

Substances:

Year:  2014        PMID: 25344603      PMCID: PMC4263865          DOI: 10.1074/jbc.M114.587675

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Impact of albumin on drug delivery--new applications on the horizon.

Authors:  Bakheet Elsadek; Felix Kratz
Journal:  J Control Release       Date:  2011-09-16       Impact factor: 9.776

2.  Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.

Authors:  Michael M Schmidt; Sharon A Townson; Amy J Andreucci; Bracken M King; Emily B Schirmer; Alec J Murillo; Christian Dombrowski; Alison W Tisdale; Patricia A Lowden; Allyson L Masci; Joseph T Kovalchin; David V Erbe; K Dane Wittrup; Eric S Furfine; Thomas M Barnes
Journal:  Structure       Date:  2013-10-10       Impact factor: 5.006

3.  Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.

Authors:  J K Kim; M Firan; C G Radu; C H Kim; V Ghetie; E S Ward
Journal:  Eur J Immunol       Date:  1999-09       Impact factor: 5.532

4.  High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization.

Authors:  D E Vaughn; P J Bjorkman
Journal:  Biochemistry       Date:  1997-08-05       Impact factor: 3.162

5.  Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells.

Authors:  Gøril Berntzen; Elin Lunde; Morten Flobakk; Jan Terje Andersen; Vigdis Lauvrak; Inger Sandlie
Journal:  J Immunol Methods       Date:  2005-03       Impact factor: 2.303

6.  Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Authors:  Jan Terje Andersen; Jason Cameron; Andrew Plumridge; Leslie Evans; Darrell Sleep; Inger Sandlie
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

Review 7.  Human serum albumin isoforms: genetic and molecular aspects and functional consequences.

Authors:  Ulrich Kragh-Hansen; Lorenzo Minchiotti; Monica Galliano; Theodore Peters
Journal:  Biochim Biophys Acta       Date:  2013-04-02

Review 8.  Albumin as a versatile platform for drug half-life extension.

Authors:  Darrell Sleep; Jason Cameron; Leslie R Evans
Journal:  Biochim Biophys Acta       Date:  2013-04-29

9.  Unfolding of acrylodan-labeled human serum albumin probed by steady-state and time-resolved fluorescence methods.

Authors:  K Flora; J D Brennan; G A Baker; M A Doody; F V Bright
Journal:  Biophys J       Date:  1998-08       Impact factor: 4.033

10.  Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.

Authors:  Jan Terje Andersen; Bjørn Dalhus; Jason Cameron; Muluneh Bekele Daba; Andrew Plumridge; Leslie Evans; Stephan O Brennan; Kristin Støen Gunnarsen; Magnar Bjørås; Darrell Sleep; Inger Sandlie
Journal:  Nat Commun       Date:  2012-01-03       Impact factor: 14.919

View more
  17 in total

1.  A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation.

Authors:  Karen Kræmmer Schelde; Karl Nicholls; Frederik Dagnæs-Hansen; Karen Bunting; Helen Rawsthorne; Birgitte Andersen; Christopher J A Finnis; Miranda Williamson; Jason Cameron; Kenneth A Howard
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

2.  Mechanism of increased clearance of glycated albumin by proximal tubule cells.

Authors:  Mark C Wagner; Jered Myslinski; Shiv Pratap; Brittany Flores; George Rhodes; Silvia B Campos-Bilderback; Ruben M Sandoval; Sudhanshu Kumar; Monika Patel; Bruce A Molitoris
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-17

3.  Antioxidant resveratrol protects against copper oxide nanoparticle toxicity in vivo.

Authors:  Sana Khalid; Nabeel Afzal; Junaid Ali Khan; Zulfia Hussain; Anas Sarwar Qureshi; Hafeez Anwar; Yasir Jamil
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-23       Impact factor: 3.000

4.  Mechanism of how carbamylation reduces albumin binding to FcRn contributing to increased vascular clearance.

Authors:  Shiv Pratap S Yadav; Ruben M Sandoval; Jingfu Zhao; Yifan Huang; Exing Wang; Sudhanshu Kumar; Silvia B Campos-Bilderback; George Rhodes; Yehia Mechref; Bruce A Molitoris; Mark C Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2020-12-07

5.  Biomonitoring of Ambient Outdoor Air Pollutant Exposure in Humans Using Targeted Serum Albumin Adductomics.

Authors:  Joshua W Smith; Robert N O'Meally; Derek K Ng; Jian-Guo Chen; Thomas W Kensler; Robert N Cole; John D Groopman
Journal:  Chem Res Toxicol       Date:  2021-04-01       Impact factor: 3.973

Review 6.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Hanna Theodora Noordzij; Inger Sandlie; Jan Terje Andersen
Journal:  Front Immunol       Date:  2015-01-26       Impact factor: 7.561

Review 7.  Albumin-based drug delivery: harnessing nature to cure disease.

Authors:  Maja Thim Larsen; Matthias Kuhlmann; Michael Lykke Hvam; Kenneth A Howard
Journal:  Mol Cell Ther       Date:  2016-02-27

8.  Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.

Authors:  Emma Davé; Ralph Adams; Oliver Zaccheo; Bruce Carrington; Joanne E Compson; Sarah Dugdale; Michael Airey; Sarah Malcolm; Hanna Hailu; Gavin Wild; Alison Turner; James Heads; Kaushik Sarkar; Andrew Ventom; Diane Marshall; Mark Jairaj; Tim Kopotsha; Louis Christodoulou; Miren Zamacona; Alastair D Lawson; Sam Heywood; David P Humphreys
Journal:  MAbs       Date:  2016-08-17       Impact factor: 5.857

9.  A human endothelial cell-based recycling assay for screening of FcRn targeted molecules.

Authors:  Algirdas Grevys; Jeannette Nilsen; Kine M K Sand; Muluneh B Daba; Inger Øynebråten; Malin Bern; Martin B McAdam; Stian Foss; Tilman Schlothauer; Terje E Michaelsen; Gregory J Christianson; Derry C Roopenian; Richard S Blumberg; Inger Sandlie; Jan Terje Andersen
Journal:  Nat Commun       Date:  2018-02-12       Impact factor: 14.919

10.  Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.

Authors:  Ralph Adams; Laura Griffin; Joanne E Compson; Mark Jairaj; Terry Baker; Tom Ceska; Shauna West; Oliver Zaccheo; Emma Davé; Alastair Dg Lawson; David P Humphreys; Sam Heywood
Journal:  MAbs       Date:  2016-06-17       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.